MA30274B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA30274B1
MA30274B1 MA31229A MA31229A MA30274B1 MA 30274 B1 MA30274 B1 MA 30274B1 MA 31229 A MA31229 A MA 31229A MA 31229 A MA31229 A MA 31229A MA 30274 B1 MA30274 B1 MA 30274B1
Authority
MA
Morocco
Prior art keywords
htslp
organic compounds
relates
lymphopoietin
thymic
Prior art date
Application number
MA31229A
Other languages
English (en)
Inventor
Michael Bardroff
Matthew Edwards
Mehmet Tur
Olaf Ratsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30274B1 publication Critical patent/MA30274B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à des anticorps de la lymphopoïétine thymique stromale humaine (hTSLP) et, plus particulièrement, à ceux qui neutralisent l'activité de hTSLP. Elle se rapporte également à des méthodes d'utilisation de molécules d'anticorps anti-hTSLP lors du diagnostique ou du traitement de troubles associés à hTSLP, tels que l'asthme, la dermatite atopique, la rhinite allergique, la fibrose, la maladie inflammatoire de l'intestin et le lymphome de Hodgkin.
MA31229A 2006-02-23 2008-09-10 Composes organiques MA30274B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0603683.4A GB0603683D0 (en) 2006-02-23 2006-02-23 Organic compounds

Publications (1)

Publication Number Publication Date
MA30274B1 true MA30274B1 (fr) 2009-03-02

Family

ID=36178659

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31229A MA30274B1 (fr) 2006-02-23 2008-09-10 Composes organiques

Country Status (24)

Country Link
US (2) US8420787B2 (fr)
EP (2) EP2341076A3 (fr)
JP (1) JP2009527235A (fr)
KR (1) KR20080099330A (fr)
CN (1) CN101389657A (fr)
AR (1) AR059867A1 (fr)
AU (1) AU2007218165A1 (fr)
BR (1) BRPI0708145A2 (fr)
CA (1) CA2638851A1 (fr)
CL (1) CL2007000478A1 (fr)
CR (1) CR10184A (fr)
EC (1) ECSP088690A (fr)
ES (1) ES2404058T3 (fr)
GB (1) GB0603683D0 (fr)
IL (1) IL193229A0 (fr)
MA (1) MA30274B1 (fr)
MX (1) MX2008010807A (fr)
NO (1) NO20083911L (fr)
PE (1) PE20080112A1 (fr)
RU (1) RU2008137531A (fr)
TN (1) TNSN08333A1 (fr)
TW (1) TW200813089A (fr)
WO (1) WO2007096149A1 (fr)
ZA (1) ZA200806490B (fr)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
DE69936105T3 (de) * 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
PL371773A1 (en) 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
CA2625681C (fr) * 2005-10-12 2016-08-02 Morphosys Ag Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
CA2628221A1 (fr) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anticorps recepteurs fzd destines au traitement du cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2667791A1 (fr) 2006-10-25 2008-05-02 Revalesio Corporation Procedes de traitement therapeutique des yeux et d'autres tissus humains a l'aide d'une solution enrichie en oxygene
JP5306214B2 (ja) 2006-10-25 2013-10-02 リバルシオ コーポレイション 混合装置
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
EP2173379B2 (fr) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions et procédés de traitement et de diagnostic d'un cancer
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (fr) * 2007-08-10 2009-02-19 Protelix, Inc. Bibliothèques universelles de domaines de liaison de la fibronectine de type iii
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
CA2703672A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procedes pour moduler la transduction de signal intracellulaire vehicule par membrane cellulaire
CA2723215A1 (fr) 2008-05-01 2009-11-05 Revalesio Corporation Compositions et methodes de traitement de troubles digestifs
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
EP2213682A1 (fr) 2009-01-30 2010-08-04 Institut Curie TSLP favorisant l'évasion immunitaire et la persistance de virus
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
ES2784123T3 (es) * 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (fr) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Agents de liaison aux recepteurs frizzled et leurs utilisations
CN104983740A (zh) 2010-05-07 2015-10-21 利发利希奥公司 用于增强生理性能和恢复时间的组合物和方法
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
JP2015502917A (ja) * 2011-10-28 2015-01-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｔｓｌｐ処置のバイオマーカーとしてのｉｌ−１９
US9732151B2 (en) 2011-11-03 2017-08-15 Merck Sharp & Dohme Corp. Biomarkers for TSLP treatment
US9181333B2 (en) 2012-07-13 2015-11-10 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2932424C (fr) * 2013-12-06 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recepteurs antigeniques chimeriques specifiques du recepteur de lymphopoietine stromale thymique et leurs procedes d'utilisation
AU2015256082C1 (en) 2014-05-07 2020-09-10 Amgen Inc. Autoinjector with shock reducing elements
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
CN111840696B (zh) 2014-06-03 2022-12-20 安姆根有限公司 可控制药物递送系统和使用方法
CA2961374A1 (fr) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
EP3206739B1 (fr) 2014-10-14 2021-12-01 Amgen Inc. Dispositif d'injection de médicament comportant des témoins visuels et sonores
WO2016065181A1 (fr) 2014-10-23 2016-04-28 Amgen Inc. Réduction de la viscosité de formulations pharmaceutiques
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
JP6484345B2 (ja) 2015-02-17 2019-03-20 アムジエン・インコーポレーテツド 固定及び／または戻りが真空によって支援された薬物送達装置
WO2016138434A1 (fr) 2015-02-27 2016-09-01 Amgen Inc. Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
EA038332B1 (ru) * 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
HRP20210650T1 (hr) * 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
AU2016402264B2 (en) * 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
WO2017189089A1 (fr) 2016-04-29 2017-11-02 Amgen Inc. Dispositif d'administration de médicament avec étiquette de messagerie
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (fr) 2016-05-16 2017-11-23 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (fr) 2016-07-01 2025-03-12 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
WO2018034784A1 (fr) 2016-08-17 2018-02-22 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement.
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CA3052204A1 (fr) 2017-02-17 2018-08-23 Amgen Inc. Mecanisme d'insertion pour dispositif d'administration de medicament
WO2018151890A1 (fr) 2017-02-17 2018-08-23 Amgen Inc. Dispositif d'administration de médicament à trajet d'écoulement de fluide stérile et procédé d'assemblage associé
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
EP3592403B1 (fr) 2017-03-06 2025-08-20 Amgen Inc. Dispositif d'administration de médicaments doté d'une fonction de prévention d'activation
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
ES3023742T3 (en) 2017-03-28 2025-06-03 Amgen Inc Plunger rod and syringe assembly system
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
WO2018237225A1 (fr) 2017-06-23 2018-12-27 Amgen Inc. Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3669004A1 (fr) * 2017-08-16 2020-06-24 Medimmune, LLC Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement
EP3668567B1 (fr) 2017-08-18 2026-02-18 Amgen Inc. Injecteur portable avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (fr) 2017-10-04 2019-04-11 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
ES2971450T3 (es) 2017-10-06 2024-06-05 Amgen Inc Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
IL273582B2 (en) 2017-11-03 2024-12-01 Amgen Inc Systems and approaches for sterilizing a drug delivery device
EP3706830B1 (fr) 2017-11-06 2024-08-07 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement et de débit
EP3707075A1 (fr) 2017-11-06 2020-09-16 Amgen Inc. Ensembles de remplissage-finition et procédés associés
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
EP3794029A4 (fr) * 2018-04-18 2022-01-12 Leadgene Biomedical, Inc. Compositions d'anticorps monoclonaux isolés et/ou de fragments de liaison à l'antigène de ceux-ci contre sulfate d'indoxyle et utilisations associées
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
CA3103681A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de medicaments
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
CA3103105A1 (fr) 2018-07-31 2020-02-06 Amgen Inc. Ensemble de trajet de fluide pour dispositif d'administration de medicament
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (fr) 2018-09-28 2020-04-02 Amgen Inc. Ensemble d'activation d'echappement de fil de muscle pour un dispositif d'administration de medicament
EP3860685A1 (fr) 2018-10-02 2021-08-11 Amgen Inc. Systèmes d'injection pour administration de médicament avec transmission de force interne
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
WO2020081480A1 (fr) 2018-10-15 2020-04-23 Amgen Inc. Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
EP3873563A1 (fr) 2018-11-01 2021-09-08 Amgen Inc. Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
CN109678957B (zh) * 2018-12-06 2021-04-06 浙江工业大学 一种抗人tslp单克隆抗体及其制备与应用
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
CA3147044A1 (fr) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents qui interferent avec la signalisation du recepteur de lymphopoietine stromale thymique (tslp)
WO2021041067A2 (fr) 2019-08-23 2021-03-04 Amgen Inc. Dispositif d'administration de médicament doté de composants configurables de mise en prise de protection d'aiguille et méthodes associées
EP4025602A4 (fr) * 2019-09-04 2023-12-13 Biosion, Inc. Anticorps se liant à tslp et leurs utilisations
PH12022551022A1 (en) 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
AU2020400221A1 (en) * 2019-12-13 2022-05-19 Harbour Biomed (Shanghai) Co., Ltd. Anti-TSLP antibody and uses thereof
CN111883211B (zh) * 2020-08-07 2021-04-23 张哲� 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
TW202219066A (zh) * 2020-11-12 2022-05-16 大陸商上海濟煜醫藥科技有限公司 一種ｔｓｌｐ抗原結合蛋白及其應用
US20250277022A1 (en) * 2021-02-04 2025-09-04 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
EP4302778A4 (fr) * 2021-03-03 2025-03-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Composition pharmaceutique contenant un anticorps anti-tslp
JP2024523779A (ja) 2021-05-21 2024-07-02 アムジェン インコーポレイテッド 薬物容器用の充填レシピを最適化する方法
CN115433275B (zh) * 2021-06-02 2026-02-24 启愈生物技术(上海)有限公司 抗胸腺基质淋巴细胞生成素（tslp）抗体及其用途
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025108344A1 (fr) * 2023-11-22 2025-05-30 上海华奥泰生物药业股份有限公司 Protéine de liaison à l'antigène ciblant tslp et utilisation
WO2026030152A1 (fr) 2024-07-29 2026-02-05 Amgen Inc. Système et procédé d'évaluation de la transférabilité d'une recette de remplissage

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2002526079A (ja) 1998-09-21 2002-08-20 シェーリング コーポレイション ヒトインターロイキン−ｂ５０、治療的使用
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
CA2430013C (fr) 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
AU2003208888B2 (en) 2002-02-01 2006-10-19 Merck Sharp & Dohme Llc Uses of mammalian cytokine; related reagents
US20060171943A1 (en) 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin

Also Published As

Publication number Publication date
EP2341076A3 (fr) 2011-08-24
ZA200806490B (en) 2009-06-24
RU2008137531A (ru) 2010-03-27
CN101389657A (zh) 2009-03-18
PE20080112A1 (es) 2008-03-13
EP1991583B1 (fr) 2012-12-19
CL2007000478A1 (es) 2008-03-14
US8420787B2 (en) 2013-04-16
CR10184A (es) 2008-12-03
US20130323237A1 (en) 2013-12-05
EP1991583A1 (fr) 2008-11-19
TW200813089A (en) 2008-03-16
MX2008010807A (es) 2008-09-01
ECSP088690A (es) 2008-09-29
ES2404058T3 (es) 2013-05-23
KR20080099330A (ko) 2008-11-12
AR059867A1 (es) 2008-05-07
AU2007218165A1 (en) 2007-08-30
CA2638851A1 (fr) 2007-08-30
WO2007096149A1 (fr) 2007-08-30
EP2341076A2 (fr) 2011-07-06
NO20083911L (no) 2008-11-05
US20090186022A1 (en) 2009-07-23
GB0603683D0 (en) 2006-04-05
TNSN08333A1 (en) 2009-12-29
IL193229A0 (en) 2009-02-11
JP2009527235A (ja) 2009-07-30
BRPI0708145A2 (pt) 2011-05-17

Similar Documents

Publication Publication Date Title
MA30274B1 (fr) Composes organiques
MA29869B1 (fr) Molecules organiques
Speerforck et al. Different biogenetic causal explanations and attitudes towards persons with major depression, schizophrenia and alcohol dependence: Is the concept of a chemical imbalance beneficial?
JP7650803B2 (ja) てんかんと関連する併存症の処置におけるカンナビノイドの使用
Yang et al. Bifidobacterium in the gut microbiota confer resilience to chronic social defeat stress in mice
Jang et al. Symptom severity and challenging behavior in children with ASD
DE602007002792D1 (de) Verbindungen und zusammensetzungen als ppar-modulatoren
ATE555814T1 (de) Radioaktive mittel für die in vivo pet-bildgebung von ccr5
Taghavi et al. The influence of socio-demographic, health and work-related factors on health-related quality of life among Iranian industrial workers
Jangra et al. Knowledge and awareness among physiotherapy students to combat COVID-19: A questionnaire based study
Bibolar et al. Gut Feelings: Linking Dysbiosis to Depression—A Narrative Literature Review
Copeland et al. Kynurenine metabolism is altered in mdx mice: a potential muscle to brain connection
Khalil et al. The Neurobiophilia Index
Castelo-Martínez et al. Harmonizing the oral-brain axis: Music-induced microbiota shifts in age-related cognitive disorders and healthy aging
Deng et al. Frailty, mental disorders, and metabolic syndrome: a genetic association and mediation Mendelian randomization study
García et al. Long COVID: Clinical features and multidisciplinary approach
Lee Effects of self esteem, impulsive behavior and mental health on cellular phone addiction of adolescents
Cetolin et al. Population aging and hospitalization for sensitive causes to primary care
Rao et al. A Community-based Study on Epidemiology, Comorbidities, and Clinical Correlates of Dhat Syndrome in India
Taylor et al. 402 Quantifying Heavy Metals in Interstitial Fluid for Remote Monitoring of Chronic Exposures
ZHENG et al. Associations of movement behaviors with anxiety and depressive symptoms in COVID-19 patients
Cassilly et al. Understanding the Role of the Gut Microbiome in Immune Homeostasis
Shobnam et al. Targeting Pollutants in the Treatment and Prevention of Atopic Dermatitis
Perlovsky et al. The grammatical roots of Jihadism: How cognitive science can help us understand the war on terror
Horikawa P427 Eosinophils in nasal discharge and nasal cavity culture in children